ICON plc — FY2021 Form 20-F
Reporting period: Year ended December 31, 2021; this is an annual report, not a standalone fourth-quarter filing. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars. ICON completed its acquisition of PRA Health Sciences on July 1, 2021, so reported 2021 results include PRA only from that date; the 2020 comparison excludes PRA.
Business context and material developments
ICON provides outsourced clinical development, laboratory, data, and commercialization services to pharmaceutical, biotechnology, medical-device, government, and public-health organizations. Following the PRA merger, ICON reported approximately 38,330 employees in 142 locations across 53 countries. The merger consideration was approximately $12.0 billion, funded partly with cash, shares, and new debt.
ICON issued 27.4 million shares to PRA shareholders and recorded preliminary acquisition goodwill of $8.1 billion and intangible assets of $4.9 billion. Purchase accounting remained provisional at year-end, with completion expected by June 30, 2022.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $5.481 billion | $2.797 billion |
| Income from operations | $378.5 million; 6.9% margin | $391.5 million; 14.0% margin |
| Adjusted income from operations | $607.9 million; 11.1% margin | $408.8 million; 14.6% margin |
| Net income attributable to ICON | $153.2 million | $332.3 million |
| Diluted earnings per share | $2.25 | $6.15 |
| Net cash from operating activities | $829.1 million | $568.0 million |
| Cash and cash equivalents | $752.2 million | $840.3 million |
| Total debt, net of issuance costs and discount | $5.436 billion | $348.5 million |
Revenue rose 95.9% (94.5% in constant currency), principally due to the PRA acquisition and recovery from COVID-19 disruption. Because PRA is included for only six months and the prior year excludes it, reported growth and margins are not directly comparable. Unaudited pro forma results, assuming the merger occurred January 1, 2020, show revenue of $7.462 billion and net income of $340.9 million for 2021, versus revenue of $5.981 billion and a net loss of $149.7 million for 2020; these figures are illustrative and exclude anticipated synergies and certain integration effects.
Operating income declined $13.0 million despite the larger business. The reported operating margin contracted to 6.9%, reflecting acquisition-related amortization and merger costs, among other factors. Adjusted operating income increased 48.7%, but adjusted margin also fell versus 2020. Merger-related transaction and integration expense was $198.3 million; restructuring expense was $31.1 million. Amortization expense rose to $239.5 million, largely due to acquired intangible assets. Interest expense increased to $182.4 million, including $75.4 million of transaction and one-time financing costs and other financing charges.
Operating cash flow increased to $829.1 million. Investing cash outflow was $6.024 billion, mainly reflecting $5.914 billion of net cash consideration for PRA and $93.8 million of capital expenditure. Financing cash inflow was $5.115 billion, primarily reflecting merger financing. Cash declined $88.1 million during the year. Days’ revenue outstanding fell to 31 days from 57 days.
Year-end total assets were $17.387 billion and shareholders’ equity was $8.067 billion. Debt consisted principally of a $5.001 billion senior secured term loan and $500 million of 2.875% secured notes. The term loan matures in July 2028; the notes mature in July 2026. The term-loan rate was 2.75% at year-end, with a LIBOR floor and variable-rate exposure. The $300 million revolving facility was undrawn apart from $4.1 million of letters of credit. ICON reported compliance with material debt covenants. The filing does not provide a standalone current ratio or a specific cash-flow forecast.
Contracted unsatisfied performance obligations were $13.3 billion; ICON expected approximately 48% to be recognized over the next 12 months, while cautioning that cancellations or delays may reduce or defer conversion. No cash dividends were expected for the foreseeable future.
Outlook, commentary, and key risks
- Management described continued revenue and net-income recovery as COVID-19 impacts eased, while warning that variants could still disrupt patient and investigator travel, trial monitoring, and laboratory sample collection and analysis.
- ICON expected approximately $150 million of run-rate cost synergies and tax savings from the merger, targeted within about four years. These are expectations, not guaranteed outcomes; management anticipated additional integration expenses.
- Key execution risks include PRA integration, employee retention, realizing synergies, and maintaining service quality and operating efficiency. The combined company’s larger debt burden raises interest, refinancing, covenant, and financial-flexibility risks; the term loan has variable-rate exposure and LIBOR transition uncertainty.
- Business risks include customer concentration, project delays or cancellations, contract underpricing and cost overruns, patient and investigator recruitment, competition and CRO consolidation, and dependence on pharmaceutical and biotech R&D spending.
- Other disclosed risks include COVID-19, cybersecurity and privacy, clinical-trial regulatory compliance, litigation and liability claims, foreign-exchange and tax-rate changes, and political or regulatory developments, including unrest in Eastern Europe.
- Management assessed disclosure controls as effective. Management and the auditor excluded PRA’s internal controls from the year-end assessment pending integration; PRA represented 10% of total assets and 38% of 2021 revenue. The auditor gave unqualified opinions on the financial statements and on the controls included in its audit.
Important facts for investors to verify
- Review the full-year results alongside the unaudited pro forma figures to distinguish organic performance from the six months of acquired PRA results.
- Track purchase-accounting finalization, goodwill and intangible valuations, and the resulting amortization and deferred-tax effects.
- Assess debt repayment, variable-rate interest exposure, covenant headroom, and progress on the LIBOR-to-replacement-rate transition.
- Monitor integration costs, employee retention, and delivery of the approximately $150 million synergy target and stated timetable.
- Evaluate conversion and cancellation risk within the $13.3 billion performance obligation, as well as customer concentration and clinical-trial execution risks.
- Note that the board authorized a new share-repurchase program of up to $100 million on February 18, 2022; the company reported $80.9 million repurchased by March 1, 2022.